

A New Competitive Inhibitory Monoclonal Antibody to Carboxypeptidase A (CPA)

Mei DU¹, Sheng JIN^{1,*}, Zhen Quan GUO²

¹College of Chemistry and Molecular Engineering, Peking University, 100871

²College of Life Science, Peking University, 100871

Abstract: The monoclonal antibody ID₁₁D₇ to carboxypeptidase A (CPA) was prepared. The inhibitory effect of McAb ID₁₁D₇ on the peptidase activity of CPA was measured. The result reflects that the McAb ID₁₁D₇ can competitively inhibit the peptidase activity of CPA with an apparent inhibitory constant of 6.3×10^{-9} M. Based on this work, the McAb ID₁₁D₇ can be used as idiotypic antigen to prepare anti-idiotypic catalytic antibody with the peptidase activity similar to CPA.

Keywords: Monoclonal antibody, carboxypeptidase A (CPA), competitive inhibition, peptidase activity.

Catalytic antibodies are a new class of biocatalysts, and have been used to catalyze many types of chemical reaction successfully¹. At present, it is difficult to use catalytic antibodies to catalyze the hydrolysis of amide bond. How to design and prepare the catalytic antibodies that can effectively catalyze the hydrolysis of amide bond has been an unsolved problem. But the hydrolysis and synthesis of amide bond are very important chemical and biological reactions. Therefore, to produce the catalytic antibodies which can catalyze the hydrolysis of amide bond is a significant research work..


A method of preparing catalytic antibodies is to produce anti-idiotypic antibodies to enzyme in order to obtain the catalytic antibodies which may have similar activity to natural enzyme. A. Friboulet successfully produced the anti-idiotypic antibody to acetylcholinesterase. This anti-idiotypic antibody has the similar enzymatic activity to acetylcholinesterase². Carboxypeptidase A (CPA) catalyzes the hydrolysis of the C-terminal amide bond³. Therefore, with carboxypeptidase A (CPA) to produce its anti-idiotypic antibody, we may obtain the catalytic antibody with the peptidase activity similar to CPA. The key step of this method is to produce the first Ab (Ab₁) which combines with the active sites of CPA and competitively inhibits the peptidase activity of CPA.

Balb/c mice were immunized with CPA. By means of cell fusion, ELISA assay, subcloning and the kinetic inhibition experiments, we obtained a monoclonal antibody ID₁₁D₇ which competitively inhibits the peptidase activity of CPA. The McAb ID₁₁D₇ was identified as IgG₁ subclass, binding constant to CPA is 9.8×10^8 M⁻¹.

The inhibition experiment of the peptidase activity of CPA with McAb ID₁₁D₇ was performed. 2 μg CPA (5×10^{-8} M) was incubated with increasing concns. (1.8×10^{-8} —5.4

$\times 10^{-8}\text{M}$) of McAb ID₁₁D₇ for 1 hr at room temperature. Then the residual peptidase activity was measured in a substrate concentrations range of ($0.4 \times 10^{-3}\text{M} \sim 1.0 \times 10^{-3}\text{M}$). A Dixon plot of the experimental data obtained is given in **Figure 1**.

Figure 1. Dixon plot representing the inhibition of the rate of hydrolysis of hippuryl-L-phenylalanine (V) with CPA by McAb ID₁₁D₇ (I). K_i: inhibitory constant; Substrate concns. used: ① $1.0 \times 10^{-3}\text{M}$; ② $0.8 \times 10^{-3}\text{M}$; ③ $0.6 \times 10^{-3}\text{M}$; ④ $0.4 \times 10^{-3}\text{M}$



The result reflects in a low range of molar concentrations ($1.8 \times 10^{-8} \sim 5.4 \times 10^{-8}\text{M}$) of McAb ID₁₁D₇, the McAb ID₁₁D₇ shows its inhibition of the peptidase activity of CPA, with an apparent inhibitory constant $6.3 \times 10^{-9}\text{M}$. That suggests the McAb ID₁₁D₇ combines with the active sites of CPA, and is good for being used as idiotypic antigen to produce the anti-idiotypic antibody which may have the peptidase activity similar to CPA.

Acknowledgments

This project was supported by the National Natural Science Foundation of China and the President's Foundation of Peking University.

References

1. N. R. Thomas, *Applied Biochemistry and Biotechnology*, **1994**, 47, 347.
2. A. Friboulet, L. Izadyar, B. Avalue, *Applied Biochemistry and Biotechnology*, **1994**, 47, 229.
3. J. F. Sebastian, W. Y. Lo, *Can. J. Biochem.*, **1978**, 56, 29.

Received 7 January 1999